Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )
"We are pleased to see our core technology patent validated in theseEuropean countries," said Neuralstem CEO, Richard Garr. "We expect this to bethe first of many as our entire patent portfolio makes its way through theEuropean process. In allowing this patent, the European Patent Office has nowjoined with the U.S. Patent Office in rejecting any arguments that the body ofStem Cells Inc. patents and publications, noted in the examinations, in anyway prevents Neuralstem's patents from issuing."
Advertisement
About Neuralstem
Neuralstem's patented technology enables, for the first time, the abilityto produce neural stem cells of the human brain and spinal cord in commercialquantities, and the ability to control the differentiation of these cells intomature, physiologically relevant human neurons and glia.
Major Central Nervous System diseases targeted by the Company withresearch programs currently underway include: Ischemic Paraplegia, TraumaticSpinal Cord Injury and ALS. The company's cells have extended the life of ratswith ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, incollaboration with Johns Hopkins University researchers, and also reversedparalysis in rats with Ischemic Spastic Paraplegia, as reported inNEUROSCIENCE on June 29, 2007, in collaboration with researchers at Universityof California San Diego.
The company has also developed immortalized human neural stem cells forin-vitro use in drug development for the academic and pharmaceutical markets.For further information, please visit http://www.neuralstem.com.
This news release may contain forward-looking statements made pursuant tothe "safe harbor" provisions of the Private Securities Litigation Reform Actof 1995. Investors are cautioned that such forward-looking statements in thispress release regarding potential applications of Neuralstem's technologiesconstitute forward-looking statements that involve risks and uncertainties,including, without limitation, risks inherent in the development andcommercialization of potential products, uncertainty of clinical trial resultsor regulatory approvals or clearances, need for future capital, dependenceupon collaborators and maintenance of our intellectual property rights. Actualresults may differ materially from the results anticipated in theseforward-looking statements. Additional information on potential factors thatcould affect our results and other risks and uncertainties are detailed fromtime to time in Neuralstem's periodic reports, including the annual report onForm 10-KSB for the year ended December 31, 2007 and subsequent quarterlyreports, if any.
SOURCE Neuralstem, Inc.
